Several promising experimental drug candidates fail successive clinical trials due to insufficient delivery across the BBB and the subsequent expelling of the therapeutic payload through efflux pumps (ABC transporters), which leads to severe side effects such as diabetes, seizures, and toxicity. Here, ABCG2 is linked to diabetes mellitus.